Business · 06/04/2012Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for VIIBRYD Patent Extension
Summary
The Food and Drug Administration has officially set a regulatory review period for the patent extension of VIIBRYD, a human drug product, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →